

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

International Application No. : PCT/EP00/06211
 International Filing Date : July 4, 2000
 U.S. Serial No. : 10/030,688
 Deposit Date U.S. Nat'l Phase : January 14, 2002
 Priority Date(s) Claimed : July 12, 1999
 Applicant(s) : Britta SUENDERMANN et al.
 Title: SERIPANCRIN

**RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS
 FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
 AND/OR AMINO ACID SEQUENCE DISCLOSURES
 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)**

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 11213-1450

Sir:

In response to the Notification dated November 25, 2003:


- ☐ Attached is a Declaration and Power of Attorney in compliance with 37 CFR § 1.53 along with the late filing surcharge of \$65.00/\$130.00
- ☐ Applicant(s) include an executed assignment and Recordation Form Cover Sheet with the recordation fee of \$40.00 (Check No.).
- ☐ Attached is a copy of the Notification of Defective Response.
- ☐ Applicant(s) request that the time for taking action in this case be extended pursuant to 37 CFR 1.136(a) for a period of one/two/three/four/five month(s) along with the fee of \$110.00/\$410.00/\$930.00/\$1450.00/\$1970.00.
- ☐ Applicant(s) are entitled to small entity status.
- ☐ Attached is a verified English translation of the PCT publication along with the fee of \$130.00.
- ☐ Attached is a Preliminary Amendment.
- ☐ Applicant(s) include the extra claims fee of \$ for claims in excess of 20 \$18/\$9 per additional claim, for independent claims in excess of 3 \$84/\$42 per additional claim, and/or \$280 for multiple dependent claims.
- ☒ Attached is the Sequence Disclosure (paper/disk versions). Applicants affirm that the attached paper and disk versions of the sequence listing are identical and do

not contain new matter

- ☐ Attached is an Application Data Sheet (ADS).
- ☐ Attached are the substitute drawings as required.

Attached is a check in the amount of \$. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402.

Respectfully submitted,



Anthony J. Zelano
Registration No. 27,969
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703)243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-2353

Date: January 26, 2004



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOV 28 2003

U.S. APPLICATION NUMBER NO. 10/030,688 ✓	FIRST NAMED APPLICANT Britta Sundermann	ATTY. DOCKET NO. MERCK 2353 ✓
---	--	----------------------------------

INTERNATIONAL APPLICATION NO.

PCT/EP00/06211 ✓

I.A. FILING DATE

PRIORITY DATE

07/04/2000 ✓

23599

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
2200 CLARENDON BLVD.
SUITE 1400
ARLINGTON, VA 22201

CASE

ACTION

DUE DATE

SEQ. DISCL. DUE
1/25/04
cup

CONFIRMATION NO. 90261 ✓

371 FORMALITIES LETTER



OC000000011335808

Date Mailed: 11/25/2003

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e) and PCT Rule 13ter.1(a)(ii).
 - **APPLICANT MUST PROVIDE:**
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

CASE _____

ACTION _____

DUE DATE _____

LAMONT M HUNTER

Telephone: (703) 305-3686

PART 1 - ATTORNEY/APPLICANT COPY

DKT-D
11/28/03
PML

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/030,688	PCT/EP00/06211	MERCK 2353

FORM PCT/DO/EO/922 (371 Formalities Notice)